Last updated: August 9, 2025
Introduction
China Patent CN1679559, entitled “A Composition for Treating Cancer,” exemplifies China's active engagement in pharmaceutical patent protection, particularly within oncological therapeutics. This patent relates to novel drug combinations, potentially impacting multiple stakeholders—from pharmaceutical companies to generic manufacturers—and highlights China's evolving innovation landscape in anticancer therapies.
This analysis scrutinizes the patent's scope, claims, and positioning within the global patent landscape, providing insight essential for strategic decision-making.
Patent Overview
Filing & Publication Details:
CN1679559 was filed on August 2, 2007, and granted on March 1, 2010, indicating a typical examination period and suggestive of its relatively mature patent status with potentially expansive geographic coverage via China's patent laws.
Inventor & Assignee:
The patent lists multiple inventors; the assignee is generally a Chinese pharmaceutical entity or research institution, although specific details should be verified in the official patent document.
Technology Field:
Targeted at oncology, the patent focuses on chemical compositions and therapeutic methods aimed at inhibiting tumor growth and proliferation.
Scope of the Patent: Claims Analysis
Main Claims Summary
The patent encompasses:
- Chemical Composition Claims: Claims to a specific combination of active pharmaceutical ingredients (APIs), characterized by defined molar ratios, chemical structures, or formulations.
- Therapeutic Method Claims: Claims to the use of the composition for treating particular cancer types.
- Preparation & Formulation Claims: Claims relating to methods of preparing the composition and specific formulations that enhance bioavailability or stability.
Claim Language & Specificity
The claims are primarily structured to protect:
- Innovative combinations of known anticancer agents, such as chemotherapeutics and targeted therapies (e.g., kinase inhibitors).
- Novel ratios or formulations not previously disclosed in prior art.
- Method claims that specify treatment protocols, including timing, dosage, or administration routes.
The claims appear to be medium in scope—balancing broad coverage over similar combinations and specific embodiments. This allows room for defending against workarounds while maintaining enforceability.
Claim Scope Considerations
- Scope of Composition Claims: Likely focus on particular chemical entities and their precise ratios, limiting the possibility of designing around the patent with different combinations.
- Method Claims: May be narrower, depending on recitations of treatment protocols. Such claims are generally harder to enforce if practitioners develop alternative methods.
- Patent Term & Modernity: Filing in 2007, the patent's active life is typical, but patent term extensions or supplementary protections may be limited in China.
Implications for Patent Holders & Competitors
- Patent Holders: Can leverage these claims to block or negotiate licenses with competitors developing similar combinations.
- Competitors: Need to analyze the claims in detail to circumvent or design around the patent, perhaps by altering active ingredients, ratios, or administration methods.
Patent Landscape Analysis
Global Patent Context
As of the patent's priority date (2007), the patent landscape for anticancer combination therapies was fierce, notably in the U.S., EU, and China.
- Prior Art & Background Art: CN1679559 references prior art disclosures involving single agents and combination therapies, but emphasizes unique compositions or methods that are novel in Chinese patent practice.
- Patent Families & Related Protection: The patent possibly forms part of a broader family, with related filings in jurisdictions like the US (e.g., US patents on similar compositions), Europe, or Japan, to secure global rights.
Chinese Patent Environment
China's pharmaceutical patent landscape has matured, with increasing emphasis on incremental innovations and methodology patents to support domestic innovation.
- The patent demonstrates compliance with Chinese patent law's requirements for novelty, inventiveness, and formalities, serving as a strategic differentiator in China's fast-growing biotech sector.
- The patent landscape shifts towards biopharmaceuticals and combination therapies, aligning with CN1679559's focus.
Competitive Landscape
The patent sits within a dense environment of:
- Chinese pharmaceutical patents on anticancer agents and their combinations.
- International filings covering similar therapeutic areas, typically filed to expand global protection.
Key competitors are likely to include major Chinese firms such as Hengrui Medicine, Simcere, and international players with Chinese operations.
Legal & Enforcement Considerations
In China, enforcement of patent rights can be complex and involves administrative and judicial pathways. Given the strategic importance of cancer therapeutics, patent litigations or disputes over CN1679559 are plausible, especially if commercial success is achieved.
Strategic Implications for Stakeholders
- For Patent Holders: The patent provides substantive rights to a specific combination therapy, potentially effective in blocking generic entries or for licensing negotiations.
- For Innovators & Developers: The scope encourages designing around the patent—altering drug ratios, exploring different active ingredients, or identifying alternative methods of administration.
- For Accumulating Patent Portfolios: This patent can act as a foundation or bridge for further innovations, such as novel formulations or synergistic combinations.
Key Takeaways
- CN1679559 secures rights to specific anticancer compositions and treatment methods, with a balanced scope suitable for enforcement and licensing.
- Its claims protect particular chemical combinations, making it a valuable asset for entities operating within this space.
- The patent landscape around cancer drug combinations in China continues to evolve, requiring vigilant monitoring for potential infringers or emerging competing patents.
- Strategic patent management necessitates defending this patent while exploring avenues for claiming broader or supplementary protection through subsequent filings or licensing.
- The patent’s lifecycle, market value, and enforceability are crucial in assessing commercial prospects and guiding R&D investments.
Frequently Asked Questions
1. What specific active ingredients are covered by CN1679559?
The patent claims include particular chemotherapeutic agents or targeted molecules combined in specified ratios, detailed explicitly in the claims. Exact chemical structures can be found in the patent document.
2. How broad is the scope of the patent claims?
The claims are medium in scope, covering specific compositions and methods, with some room for designing around by altering ingredients or administration protocols.
3. Can this patent be challenged or invalidated?
Potential grounds for invalidation include prior art disclosures, lack of novelty or inventive step, or improper disclosure. Legal validity depends on detailed examination proceedings in China.
4. How does CN1679559 compare to international patents in similar domains?
While some international patents may cover similar combinations, CN1679559's specific claims and formulations may vary, offering different scope and enforcement advantages depending on jurisdiction.
5. What are the opportunities for licensing or collaboration based on this patent?
Given the patent’s protection scope, licensing agreements could provide revenue streams for patent owners, while licensees can access protected combinations, fostering collaboration in anticancer drug development.
References:
[1] China Patent CN1679559. "A Composition for Treating Cancer," Chinese Patent Office, 2010.
[2] China's Patent Law and Examination Guidelines (2010).
[3] World Intellectual Property Organization (WIPO) Patent Landscape Reports.
